Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis

American Journal of Clinical Dermatology
Sheridan M Hoy

Abstract

Crisaborole ointment 2% (Eucrisa™) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged ≥ 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus severity compared with vehicle, with the effect established early and sustained over the course of treatment. Improvements in the other signs of atopic dermatitis (erythema, exudation, excoriation, induration/papulation, and lichenification) were also seen. Crisaborole ointment 2% was generally well tolerated in the short-term studies, with its favorable safety profile maintained over the longer term (up to 52 weeks) in a multicentre, extension study. Most treatment-emergent adverse events (TEAEs) were of mild to moderate severity and considered unrelated to the study medication. Moreover, the incidence of application-site pain following short- and longer-term topical therapy with crisaborole ointment 2% was low. In conclusion, crisaborole ointment 2% is an effective and generally well tolerated new topical option fo...Continue Reading

References

Jan 17, 2007·The British Journal of Dermatology·J CallenB U Wintroub
Jun 16, 2010·Annals of Dermatology·Thomas Bieber
Sep 7, 2012·The Journal of Allergy and Clinical Immunology·Julia K GittlerEmma Guttman-Yassky
Oct 17, 2012·Seminars in Cutaneous Medicine and Surgery·Charles N EllisLawrence F Eichenfield
Feb 5, 2013·The Journal of Allergy and Clinical Immunology·Lynda SchneiderDana Wallace
Dec 3, 2013·Journal of the American Academy of Dermatology·Lawrence F EichenfieldRobert Sidbury
May 13, 2014·Journal of the American Academy of Dermatology·Lawrence F EichenfieldRobert Sidbury
Jul 3, 2016·American Journal of Clinical Dermatology·Diane Wang, Lisa A Beck
Aug 16, 2016·Seminars in Cutaneous Medicine and Surgery·Lawrence F EichenfieldAlan D Irvine
Aug 22, 2017·Journal of the American Academy of Dermatology·Lawrence F EichenfieldEduardo Tschen

❮ Previous
Next ❯

Citations

May 5, 2018·Expert Opinion on Therapeutic Patents·Alessio NocentiniJean-Yves Winum
Dec 28, 2018·Expert Review of Clinical Immunology·Aisleen Diaz, Emma Guttman-Yassky
Apr 20, 2019·Expert Opinion on Pharmacotherapy·Vignesh RamachandranLindsay C Strowd
Jun 13, 2018·Journal of Food Science and Technology·Yu-Pei ChenLeong-Perng Chan
Jan 3, 2019·Expert Opinion on Pharmacotherapy·Katelyn R GlinesSteven R Feldman
Dec 15, 2020·Dermatologic Therapy·Nafise YazdanianAzadeh Goodarzi
Feb 14, 2021·Indian Journal of Dermatology, Venereology and Leprology·Anupam DasBhushan Madke
Aug 25, 2019·Bioorganic Chemistry·Krzysztof M BorysAgnieszka Adamczyk-Woźniak
Mar 5, 2021·Pharmacology & Therapeutics·Xiaoliang YangKenji Kabashima
Apr 22, 2021·Clinical Ophthalmology·Crystal X HuangJoanne F Shen
May 28, 2021·Journal of Medicinal Chemistry·Jiyun SunSteven H Liang
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Paolo Saul CoghiYingjun Zhang
Oct 29, 2021·Journal of the American Academy of Dermatology·Hidehisa SaekiHidetsugu Tsubouchi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.